NATCO Pharma (NATCOPHARM) Investor presentation summary

Company overview and evolution

• Achieved global revenues of $495 million (INR 43,759 million) in FY26, exporting to 50+ countries and ranking among the top 10 generic companies by sales in Canada.

• Operates 9 manufacturing facilities and 2 R&D centers, with over 500 scientists and a workforce exceeding 5,000.

• Evolved from a domestic player in the 1980s to a global leader in niche and complex generics, with significant milestones in oncology, neurology, and crop health sciences.

• Expanded through strategic acquisitions and investments in advanced therapies, including cell and gene therapy and xenotransplantation.

Financial performance

• Delivered strong operational growth with an 8% CAGR in revenue and 11% CAGR in PAT over the past decade.

• FY26 consolidated revenue reached INR 43,759 million, with EBITDA of INR 17,341 million and PAT of INR 14,185 million.

• Maintained robust margins: FY26 EBITDA margin at 39.6% and PAT margin at 32.4%.

• Net worth increased to INR 92,211 million by March 2026, with a return on equity of 15.4%.

Business segments and global reach

• Export formulations contributed INR 32,345 million in FY26, focusing on niche opportunities in the US, Canada, Brazil, and emerging markets.

• Domestic formulations generated INR 4,409 million, with 20+ brands leading in prescriptions and a strong sales network.

• Crop Health Sciences (CHS) achieved INR 1,382 million in revenue, launching innovative agrochemical products and planning a demerger.

• Strategic API business supports both third-party sales and captive use, with 45 active US DMFs and a focus on complex oncology molecules.